Reading ISPC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ISPC free→Reading ISPC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ISPC free→QuarterlyIQ Insights · ISPC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Mar…
Unregistered Sales of Equity Securities. The issuance and sale of the Shares and Pre-Funded Warrants at the Closing were made, and the issuance of the Warrant Shares upon exercise of the Pre-Funded Warrants will be made, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. The Investors r…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2025, on November 19, 2025, the Company received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.…
Entry into a Material Definitive Agreement. On May 8, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell 488,281 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock” or “Shares”), at a purchase price of $5.12 per Share. In lieu of Shares that would otherwise…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 17, 2026, Ms. Siyun Yang resigned as a director of iSpecimen Inc. (the “Company”), effective immediately. Ms. Yang’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms. Yang had served as an independent director since February 2025 and was a member of the Audit Committee and the Nomina…
Regulation FD Disclosure. On February 6, 2026, iSpecimen Inc. (the “Company”) issued two press releases. The first press release announced the successful completion of Milestone 2 in the Company’s digital transformation program powered by SalesStack Solutions and the activation of the Company’s live production marketplace. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The second press release highlights recent operational achievements demonstrat…
Entry into a Material Definitive Agreement. As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), completed a private placement, on December 31, 2025, of its Series C Convertible Non-Voting Preferred Stock. On December 31, 2025, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with IR Agency LLC (the “Consultant”…
Unregistered Sales of Equity Securities. The issuance and sale of the Series C Preferred Stock at the Closing was made, and the issuance and sale of the additional Conversion Shares will be made, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D promulgated thereunder, as transactions by an issuer not involving a public offering. The Investors represented that they are…
Entry into a Material Definitive Agreement. On December 30, 2025, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to sell, and the Investors agreed to purchase, 6,875 shares of the Company’s newly-designated Series C Convertible Non-Voting Preferred Stock, par value $0.0001 per share (the “Series C Preferred St…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, iSpecimen Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 7, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field to serve as Chief Executive Officer, Secretary, and Treasurer of the Company, effective immediately. Ms. Field will continue to serve as President of the Company. On the same date, Mr. Robert Bradley Lim stepped down as Chief Exe…
Regulation FD Disclosure. On August 21, 2025, iSpecimen Inc. (the “Company”) issued a press release announcing the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This achievement marks the installation of the new Salestack platform and provisioning of modern infrastructure. The Company is now positioned to advance to Milestone 2 (Integration), which will focus on connecting all parts of the Company’s business to the Salestack platfor…
Regulation FD Disclosure. On July 31, 2025, the Company issued a press release announcing the pricing of the Private Placement described in
Entry into a Material Definitive Agreement. On July 31, 2025, iSpecimen Inc. (Nasdaq: ISPC) (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company issued and sold, in a private placement (the “Private Placement”), an aggregate of 1,559,828 shares of its common stock, par value $0.0001 per share (the “Common Stock”), or, in lieu thereof, pre-funded warrants to purchase shares of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately. Mr. Paolone had served on the Board since September 2024 and as Chairman since February 2025. Mr. Brooks had served on the Board since June 2021. To the Company’s knowledge, ne…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 4, 2025, iSpecimen Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. As reported in the Company’s Quarterly Rep…
Changes in Registrant’s Certifying Accountant. On March 7, 2025, iSpecimen Inc. (the “Company”) was notified that Wolf & Company, P.C. (“Wolf & Company”) resigned as the Company’s independent registered public accounting firm, effective immediately. Wolf & Company’s audit reports for the fiscal years ended December 31, 2023, and December 31, 2022, did not contain an adverse opinion, or a disclaimer nor was it qualified or modified as to uncertainty, audit scope, or accounting principles. Howe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. This Amendment No. 1 to the Original Form 8-K is being filed by iSpecimen Inc. to disclose the terms of the employment agreement (the “Employment Agreement”) entered into with Ms. Katharyn Field on February 28, 2025, under which Ms. Field will receive an annual base salary of $240,000, payable in accordance with the Company’s standard payroll sched…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 19, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field as President of the Company, effective immediately. In connection with her appointment, Ms. Field resigned as a member of the Board, and Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effe…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.